Evotec's Half-Year Report Arrives as a 10% Rebound Meets a 30% Annual Slide
Published on 08/13/2026 at 06:01 | Redaktion boerse-global.de
When Evotec publishes its audited first-half results on Thursday, the numbers will land in a market that has already priced in the worst — and, just as quickly, begun to question whether the worst is actually over. The Bremen-based drug discovery specialist enters the release with its shares up roughly 10 percent over the past seven sessions, a bounce that has lifted the stock to €3.82 at Wednesday's close, yet the equity still trades 51 percent below its November high of €7.75 and has shed 30 percent since the start of the year.
The recovery has been anything but smooth. A profit warning issued on July 13 sent the stock to a 52-week low of €3.19 the following day, and while the subsequent rebound has pushed the price about 20 percent above that trough, the stock remains roughly 11 percent beneath its 50-day moving average of €4.27 — a technical signal that the selling pressure has not fully abated.
The Guidance Cut That Reshaped the Investment Case
The preliminary figures released in mid-July painted a sobering operational picture. Group revenue for the first half fell 19 percent year-on-year to approximately €300.1 million, with the second quarter particularly weak: sales dropped 16 percent to €143.5 million. Adjusted EBITDA for the period came in at roughly minus €42.7 million.
Management's response was a dramatic downward revision of the full-year outlook. The company now guides for 2026 revenue between €570 million and €610 million, a far cry from the €700 million to €780 million previously projected. The adjusted EBITDA forecast has been reset to a loss of €70 million to €105 million, against an earlier target of breakeven to €40 million profit. Media reports attribute the revision primarily to slower revenue conversion and delays in strategic partnerships and new deal closures.
Thursday's audited report will be scrutinized for whether these revised targets hold up under closer examination — a question that carries particular weight given the scale of the adjustment.
Should investors sell immediately? Or is it worth buying Evotec?
Analyst Upgrades and a New Alliance
The market has found reasons for cautious optimism. On Monday, three analyst houses — Oddo BHF, Bernstein, and Van Lanschot Kempen — upgraded the stock, providing a notable boost and contributing to the recent run-up. Market observers have also interpreted the price action as stabilization above the July low, though sentiment remains fragile.
Operationally, Evotec has sought to signal forward momentum. Early this month, the company announced a strategic research collaboration with Odyssey Therapeutics aimed at discovering new therapies for autoimmune and inflammatory diseases. The partnership leverages Evotec's integrated, data-driven discovery platform and AI-powered data science technologies, with Evotec eligible for milestone payments tied to the successful delivery of validated hit series for specific target structures.
The deal structure — milestone-based compensation rather than upfront fees — limits Evotec's risk exposure while offering potential upside, though it also underscores how dependent the company has become on new growth catalysts following the guidance cut.
Institutional Positioning Shifts
The shareholder register has seen notable movement in recent weeks. Goldman Sachs Group reported on August 6 an increase in its voting rights stake to 13.71 percent as of that date, largely held through financial instruments. State Street, meanwhile, briefly crossed the 3 percent notification threshold in late July before dipping back below it within days.
These moves suggest institutional investors are taking a closer look at a stock that now carries a market capitalization of roughly €649.65 million — a valuation that reflects both the operational setbacks and the potential upside if the revised guidance proves conservative.
A Liquidity Cushion for the Pivot
One mitigating factor: Evotec expects to have had approximately €465.6 million in liquidity as of June 30. That capital base provides breathing room to fund the ongoing strategic repositioning and investments in AI-driven platforms while the timing of new deals stabilizes.
The question heading into Thursday's report is whether the recent share price recovery rests on fundamental ground or merely reflects a technical bounce from deeply oversold levels. With the stock still down 30 percent year-to-date and the company navigating a period of lowered expectations, the audited half-year figures will offer investors their clearest signal yet on which scenario is more likely to unfold.
Ad
Evotec Stock: New Analysis - 13 August
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
